LifeStance Health Group, Inc. (LFST) Key Metrics
LFST valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.46B
- Enterprise value
- $4.83B
- P/E (TTM)
- 90.3
- Forward P/E
- 52.6
- PEG ratio
- —
- Price / sales
- 2.8 10-yr median 2.2
- Price / book
- 3.1 10-yr median 1.9
- EV / EBITDA
- 36.7
- Dividend yield
- —
- Beta
- 1.24
LFST key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLFST valuation Price multiples at each fiscal year-end price.
LFST returns How much profit the business earns on the capital it uses.
LFST per-share figures Results divided by the shares outstanding at year-end.
LFST financial health Debt, liquidity and how easily interest is covered.
LFST efficiency & capital use Working capital cycle and where the cash goes.
LFST valuation history
LFST returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LFST debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LFST cash returned to shareholders
LFST price vs earnings per share
LFST key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $2.75B | $2.79B | $2.88B | $1.76B | $3.12B | — | — |
| Enterprise value | $2.70B | $3.12B | $3.31B | $2.13B | $3.13B | — | — |
| P/E ratio | 285.0 | — | — | — | — | — | — |
| Price / sales | 1.9 | 2.2 | 2.7 | 2.0 | 4.7 | — | — |
| Price / book | 1.8 | 1.9 | 2.0 | 1.2 | 2.0 | — | — |
| Price / free cash flow | 25.0 | 32.6 | — | — | — | — | — |
| Price / operating cash flow | 18.8 | 26.1 | — | 33.2 | 331.0 | — | — |
| EV / sales | 1.9 | 2.5 | 3.1 | 2.5 | 4.7 | — | — |
| EV / EBITDA | 34.3 | 78.4 | — | — | — | — | — |
| EV / free cash flow | 24.5 | 36.5 | — | — | — | — | — |
| Earnings yield | 0.4% | −2.1% | −6.5% | −12.3% | −9.9% | — | — |
| Free cash flow yield | 4.0% | 3.1% | −2.0% | −1.5% | −2.7% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.1% | 0.0% | — | — |
| Share price at fiscal year-end | $7.04 | $7.37 | $7.83 | $4.94 | $9.52 | — | — |
| Per share | |||||||
| Revenue per share | $3.64 | $3.30 | $2.87 | $2.42 | $2.04 | $1.01 | $0.57 |
| Earnings per share | $0.02 | −$0.15 | −$0.51 | −$0.61 | −$0.94 | −$0.10 | $0.02 |
| Operating cash flow per share | $0.37 | $0.28 | −$0.05 | $0.15 | $0.03 | −$0.02 | $0.05 |
| Free cash flow per share | $0.28 | $0.23 | −$0.16 | −$0.07 | −$0.26 | −$0.12 | $0.01 |
| Cash per share | $0.64 | $0.41 | $0.21 | $0.31 | $0.45 | $0.05 | $0.01 |
| Book value per share | $3.89 | $3.81 | $3.89 | $4.27 | $4.72 | $2.67 | −$0.45 |
| Tangible book value per share | $0.13 | −$0.10 | −$0.23 | −$0.05 | $0.12 | −$1.16 | −$1.06 |
| Capex per share | $0.09 | $0.06 | $0.11 | $0.22 | $0.29 | $0.10 | $0.04 |
| Debt per share | $0.50 | $1.28 | $1.39 | $1.35 | $0.48 | $0.98 | $0.21 |
| Shares outstanding | 391.1M | 379.1M | 367.5M | 355.3M | 327.5M | 373.6M | 373.6M |
| Change in shares outstanding | +3.2% | +3.2% | +3.4% | +8.5% | −12.3% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | 0.7% | −4.0% | −12.6% | −14.1% | −24.2% | −9.2% | — |
| Return on invested capital (ROIC) | 1.2% | −1.4% | −8.0% | −9.6% | −15.6% | 1.9% | — |
| Return on assets (ROA) | 0.4% | −2.7% | −8.7% | −10.5% | −17.6% | −4.1% | 2.0% |
| Return on tangible assets | 1.3% | −9.1% | −31.3% | −33.8% | −72.8% | −27.5% | 11.1% |
| Free cash flow margin | 7.7% | 6.9% | −5.4% | −3.1% | −12.7% | −12.4% | 1.3% |
| Income quality (OCF / net income) | 15.12 | — | — | — | — | — | 3.01 |
| Financial health | |||||||
| Total debt | $194.1M | $485.2M | $511.0M | $478.8M | $158.7M | $366.3M | $79.3M |
| Cash & short-term investments | $248.6M | $154.6M | $78.8M | $108.6M | $148.0M | $18.8M | $3.5M |
| Net debt | −$54.5M | $330.6M | $432.2M | $370.2M | $10.7M | $347.4M | $75.8M |
| Debt / equity | 0.13 | 0.34 | 0.36 | 0.32 | 0.10 | 0.37 | — |
| Debt / assets | 0.09 | 0.23 | 0.24 | 0.22 | 0.08 | 0.23 | 0.28 |
| Net debt / EBITDA | −0.69 | 8.29 | — | — | — | 39.64 | 3.91 |
| Current ratio | 1.65 | 1.37 | 1.11 | 1.33 | 2.28 | 1.00 | 0.50 |
| Quick ratio | 1.65 | 1.37 | 1.11 | 1.33 | 1.96 | 1.00 | 0.46 |
| Interest coverage | 2.1 | -1.2 | -8.9 | -10.5 | -7.4 | 0.7 | 2.8 |
| Working capital | $164.2M | $83.6M | $22.9M | $57.2M | $149.8M | $359,000 | −$27.6M |
| Invested capital | $1.47B | $1.78B | $1.86B | $1.89B | $1.56B | $1.35B | −$90.5M |
| Tangible asset value | $50.0M | −$37.9M | −$85.5M | −$17.5M | $40.1M | −$433.6M | −$395.9M |
| Net current asset value | −$266.7M | −$359.5M | −$455.3M | −$421.9M | −$115.6M | −$495.6M | −$419.7M |
| Graham number | $1.47 | — | — | — | — | — | — |
| Graham net-net per share | −$0.93 | −$1.10 | −$1.38 | −$1.32 | −$0.48 | −$1.39 | −$1.15 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $904,000 | $0 | $1.0M | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 2.5% | 1.7% | 3.8% | 9.2% | 14.2% | 10.1% | 6.7% |
| Capex / operating cash flow | 24.7% | 20.1% | — | 150.1% | 1,003.1% | — | 84.0% |
| Capex / depreciation | 0.66 | 0.30 | 0.50 | 1.15 | 1.75 | 1.23 | 2.35 |
| Stock-based compensation / revenue | 5.2% | 6.1% | 9.4% | 21.8% | 38.9% | 0.4% | 0.0% |
| SG&A / revenue | 26.8% | 29.0% | 39.1% | 45.0% | 65.3% | 24.0% | 19.6% |
| Efficiency | |||||||
| Days sales outstanding | 29.2 | 37.6 | 39.3 | 37.7 | 32.7 | 30.4 | 32.9 |
| Days of inventory on hand | — | — | 0.0 | — | 14.9 | 1.4 | 4.6 |
| Days payables outstanding | 2.5 | 6.5 | 11.5 | 11.3 | 8.6 | 12.0 | 20.2 |
| Cash conversion cycle (days) | 26.6 | 31.0 | 27.7 | 26.4 | 39.1 | 19.8 | 17.3 |
| Receivables turnover | 12.51 | 9.71 | 9.29 | 9.68 | 11.15 | 12.01 | 11.11 |
| Payables turnover | 144.15 | 55.73 | 31.68 | 32.32 | 42.67 | 30.39 | 18.10 |
| Inventory turnover | — | — | 753,569,000.00 | — | 24.48 | 255.55 | 78.97 |
| Asset turnover | 0.66 | 0.59 | 0.49 | 0.42 | 0.38 | 0.41 | 0.76 |
| Average receivables | $113.9M | $128.8M | $113.6M | $88.8M | $59.9M | $31.4M | $19.1M |
| Average payables | $6.7M | $15.2M | $23.8M | $19.3M | $10.9M | $8.0M | $8.3M |
| Average inventory | — | — | $1 | — | $19.0M | $950,500 | $1.9M |
| Intangibles / total assets | 66.7% | 70.1% | 71.8% | 70.7% | 78.1% | 91.2% | 81.8% |
Computed from LFST's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LFST valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), LifeStance Health traded at 285.0 times earnings. Based on the latest twelve months, the trailing P/E is 90.3 and the forward P/E is 52.6. LifeStance Health earned a return on equity of 0.7% and a return on invested capital of 1.2% in fiscal 2025. It ended the year with $194.1 million of debt and $248.6 million in cash and short-term investments, a net cash position of $54.5 million. The share count rose 4.7% from 373.6M to 391.1M over 6 years.
See the LFST income statement, the LFST chart for price history, or the LFST stock overview for the latest quote and news.
LFST key metrics FAQ
What is LifeStance Health's P/E ratio?
LifeStance Health's trailing P/E ratio is 90.3 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 52.6. At the end of fiscal 2025 it was 285.0.
What is LifeStance Health's EV/EBITDA?
LifeStance Health's enterprise value was 34.3 times EBITDA at the end of fiscal 2025 (enterprise value $2.7 billion, EBITDA $78.8 million); the current EV/EBITDA is 36.7.
What is LifeStance Health's return on equity?
LifeStance Health's return on equity (ROE) was 0.7% in fiscal 2025: net income of $9.7 million on average shareholders' equity of $1.5 billion.
What is LifeStance Health's ROIC?
LifeStance Health's return on invested capital was 1.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does LifeStance Health have?
LifeStance Health had total debt of $194.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.13 and more cash than debt.
What is LifeStance Health's free cash flow yield?
LifeStance Health generated $110.0 million of free cash flow in fiscal 2025, a free cash flow yield of 4.0% on its market value at year-end ($2.8 billion).
What is LifeStance Health's current ratio?
LifeStance Health's current ratio was 1.65 at the end of fiscal 2025: current assets were 1.65 times current liabilities.